About Melinta Therapeutics
Melinta Therapeutics is a company based in Morristown (United States) founded in 2000 was acquired by CorMedix in August 2025. Melinta Therapeutics has raised $186 million across 15 funding rounds from investors including Hercules Capital, Sanofi and Warburg Pincus. Melinta Therapeutics offers products and services including Innovative Therapies and Portfolio Products. Melinta Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Iterum Therapeutics, Adaptive Phage Therapeutics and Cubist Pharmaceuticals, among others.
- Headquarter Morristown, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website melinta.com
- Social LinkedIn X YouTube
- Acquired by CorMedix (Aug 2025)
- Legal Name Melinta Therapeutics, Llc
- Total Equity Funding$186M (USD)
in 15 rounds
- Latest Funding Round$75M (USD), Post-IPO
Feb 2019
- InvestorsHercules Capital
& 16 more
- Acquired by
Products & Services of Melinta Therapeutics
Melinta Therapeutics offers a comprehensive portfolio of products and services, including Innovative Therapies and Portfolio Products.
Therapies targeting acute and life-threatening illnesses for patient care.
Commercial-stage products for expanding healthcare applications.
Apps and channels of Melinta Therapeutics
its YouTube channel Melinta Therapeutics has 18 subscribers and 1 videos.
Videos from Melinta Therapeutics
The most watched videos on Melinta Therapeutics's YouTube channel, Melinta Therapeutics (18 subscribers). Click a video to play it here.
More on Melinta Therapeutics.
Funding Insights of Melinta Therapeutics
Melinta Therapeutics has successfully raised a total of $186M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $75 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $186M
- Total Rounds 15
- Last Round Post-IPO — $75M
- First Round $22M
(Dec 2001)
- Investors Count 15
Latest 10 of 15 funding rounds of Melinta Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $75M | Post-IPO | – | – | |
| Jan 2018 | $137.78M | Post-IPO | – | – | – |
| Nov 2017 | $132.91M | Post-IPO | – | – | – |
| Jun 2017 | $90M | Debt – Conventional | – | – | |
| Jun 2015 | $67M | Post-IPO | – | – | |
| Dec 2014 | $20M | Debt – Venture | – | – | |
| Feb 2014 | $70M | Post-IPO | – | – | |
| Nov 2012 | $67.5M | Post-IPO | – | – | |
| Feb 2012 | $3M | Post-IPO | – | – | |
| Jan 2011 | $20M | Series C | – | Warburg Pincus | – |
17 investors in total: 17 institutional.
Investors in Melinta Therapeutics
Melinta Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Sanofi and Warburg Pincus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | vaterahealthcare.com | - | |
Structured financing solutions are provided for the global healthcare industry by Oberland Capital. | 2013 | oberlandcapital.com | New York, United States | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
Venture capital firm | – | absventures.com | Waltham, United States | |
- | – | axiomventures.com | - | |
- | – | medimmuneventures.com | - | |
Early stage VC firm investing in the US and Korea | – | oxbio.com | Boston, United States | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
- | – | radiusventures.com | - |
Investor details for Melinta Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Melinta Therapeutics
51 people are tracked at Melinta Therapeutics (31 in leadership, 3 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Christine Ann Miller | CEO | Leadership |
Kim M Greco | Director Commercial Operations | Leadership |
Robert Parkey | Regional Sales Director South Central US | Leadership |
Kajal Preuss | Director Of Brand Marketing | Leadership |
Molly Deiss | Vice President Marketing | Leadership |
Sonia Pelkowski | Marketing Director | Leadership |
Jisoo Park | Chief Business Officer | Leadership |
Madhup K. Dhaon | Director-technical Operations | Leadership |
Kristen Allgor | Chief Human Resources Officer | Leadership |
Kelley Ford | VP, Manufacturing & Supply | Leadership |
Doug Girgenti | VP, Drug Development | Leadership |
Marianna Fedorenko | Senior Medical Science Director | Leadership |
Jennifer Allen | Senior Director, Compliance | Leadership |
Dawn Robertshaw | Director, Value & Access | Leadership |
Lindsey Ronan | Director Of Inside Sales | Leadership |
John Meyer | Director IT | Leadership |
Greg Gangemi | VP Market Access & Trade | Leadership |
Dave Baran | Vice President, Alliance Management & Strategic Projects | Leadership |
Christina Stamler | Director, HR Operations And HRIS | Leadership |
Douglas Girgenti M.D. | Vice President Of Drug Development | Leadership |
31 more people are available in the full profile.
Complete people profiles for Melinta Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Melinta Therapeutics
6 dated milestones of Melinta Therapeutics across 25 years, from founding to its latest funding, stage changes and deals.
Competitors of Melinta Therapeutics
Melinta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Iterum Therapeutics, Adaptive Phage Therapeutics and Cubist Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| cubist.com | 1993 | Lexington, United States | – | 895 | Pharmaceuticals for acute care bacterial infections are developed and commercialized. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. |
Detailed competitors of Melinta Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Melinta Therapeutics
The website of Melinta Therapeutics (melinta.com) receives about 2.8K visits a month and ranks #3,931,198 among all websites worldwide, #4,969 in Biotechnology and Pharmaceuticals.
- Monthly visits2.8K
▼ 42.1% vs previous month
- Unique visitors2K
per month
- Global rank#3,931,198
among all websites
- Category rank#4,969
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.6
- Average visit28 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Melinta Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immunogen.com | 100% | – | – | View details | |
| cmedresearch.com | 96% | – | – | View details | |
cureconnect.org | cureconnect.org | 96% | – | – | – |
idstewardship.com | idstewardship.com | 81% | – | #839,076 | – |
pod51038.outlook.com | pod51038.outlook.com | 56% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Melinta Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Melinta Therapeutics
Complete news archive for Melinta Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Melinta Therapeutics
10 companies that operate in the same segment as Melinta Therapeutics (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Melinta Therapeutics
Melinta Therapeutics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Melinta Therapeutics is headquartered in Morristown, United States. It is registered at Morristown, New Jersey, United States.
Christine Ann Miller is the current CEO of Melinta Therapeutics.
Melinta Therapeutics is a funded company, having raised a total of $186M across 15 funding rounds to date. The company's 1st funding round was a Series C of $20M, raised on Dec 2001.
Melinta Therapeutics is developing bacterial ribosome-targeting drugs for MDR infections. The company has commercialized its antibiotic, delafloxacin for acute bacterial skin and skin structure infections (Staphylococcus strains, Streptococcus strains, Enterococcus strain, E.coli, Enterobacter cloacae, Klebsiella pneumoniae, and P.aeruginosa), community-acquired bacterial pneumonia (CABP), and Complicated Urinary Tract Infections (cUTI). It is also developing a new class of antibiotics designed to overcome the resistant ESKAPE pathogens that cause hospital infections.
Melinta Therapeutics's top competitors include Spero Therapeutics, Vedanta Biosciences and Cubist Pharmaceuticals.
Melinta Therapeutics offers Innovative Therapies and Portfolio Products.
Melinta Therapeutics has 17 investors. Key investors include Hercules Capital, Sanofi, Warburg Pincus, CorMedix, and Vatera Healthcare Partners.
Melinta Therapeutics operates through Melinta Therapeutics, Llc.
Yes. Melinta Therapeutics was acquired by CorMedix in August 2025.